Anthropic (ANT.US) IPO priced at $83, above the top of its guidance range, to list on Nasdaq on Thursday.
Anthropic set its initial public offering (IPO) price at $83 per share on Wednesday, above the top of its previously announced guidance range of $70 to $78.
Anthropic, the artificial intelligence (AI) startup, priced its initial public offering (IPO) at $83 per share on Wednesday, above the top of its previously announced guidance range of $70 to $78. The developer of the Claude AI models is expected to begin trading on Nasdaq on Thursday under the ticker symbol "ANT." The listing is not only one of the most closely watched tech IPOs of the year but is also seen as an important bellwether for investor confidence in the AI industry.
Anthropic was founded in 2021 by CEO Dario Amodei and several researchers who left OpenAI. The company is known for its Claude series of AI models, primarily offering AI products and services to enterprise customers, and achieved explosive growth in 2026 on the rapid adoption of its AI coding tool Claude Code.
The company publicly filed its prospectus in October and last week set an expected IPO price range of $70 to $78 per share. The final pricing of $83 is about 6.4% above the top of the original range, reflecting strong investor demand for the AI company.
The IPO comes as the AI industry faces multiple challenges. Recently, social debate surrounding AI technology has continued to intensify and has triggered political backlash in the U.S. midterm elections. Meanwhile, NVIDIA Corporation (NVDA.US) CEO Jensen Huang was ousted last week, further heightening market uncertainty about the AI industry's outlook.
In addition, with U.S. interest rates continuing to rise, investors are increasingly concerned that rising financing costs for data center developers and emerging cloud computing service providers could undermine the sustainability of AI infrastructure investment. Against this backdrop, Anthropic's listing performance will be an important indicator of whether the market remains willing to pay high valuations for the AI industry's high-growth prospects.
Notably, Anthropic has established deep capital and commercial ties with several global tech giants. Amazon.com, Inc. (AMZN.US) and Alphabet Inc. Class C parent Alphabet (GOOGL.US) both hold stakes in Anthropic, each valued at more than $100 billion. In addition, tech companies including Alphabet Inc. Class C, Microsoft Corporation (MSFT.US), NVIDIA Corporation and AMD (AMD.US) have agreed to invest a combined $26 billion in the IPO.
At the same time, Anthropic is also a major customer of these tech giants, continuously purchasing high-cost AI computing systems from NVIDIA Corporation, Alphabet Inc. Class C, Amazon.com, Inc. and AMD. This relationshipas investor, partner and supplierunderscores Anthropic's important position in the global AI supply chain.
Financial data shows that Anthropic's revenue growth has been extremely rapid. According to the prospectus, for the first nine months ended September 30, Anthropic generated revenue of $33.24 billion, up about 1,200% from the same period last year. However, the company recorded a net loss of $104 billion for the same period, most of which came from accounting effects related to changes in the fair value of convertible notes and derivative liabilities. By comparison, the net loss for the same period in 2025 was $25.1 billion.
In an updated regulatory filing, Anthropic further disclosed that as of the end of October, its annualized revenue run rate was approximately $81 billion, an increase of $10 billion from the end of September, indicating that its business scale is still expanding rapidly.
This growth was mainly driven by surging demand from enterprise customers for the Claude models and the Claude Code programming tool. Anthropic is currently competing with OpenAI and Alphabet Inc. Class C for enterprise AI market share. As AI models are gradually integrated into software development, enterprise operations and automated workflows, enterprise customers are becoming the core market that major AI companies are vying for.
Competitor OpenAI has also confidentially filed for an IPO and said it may go public in 2027. This means that in the coming year, global capital markets may see multiple influential AI companies.
However, Anthropic's rapid expansion also comes with significant risks. This year, the company has been involved in two high-profile disputes with the U.S. government over issues including AI safety, regulation and national security. Its prospectus contains more than 90 pages of risk factors, reminding investors to pay attention to uncertainties arising from AI technology development, regulatory policy, commercial competition and massive capital expenditures.
Anthropic CEO Dario Amodei said in an IPO roadshow video that if AI can be developed correctly, humanity could enter a new era capable of solving many long-standing problems. But he also stressed that the company must carefully manage the various risks that AI technology may bring while achieving sustainable commercial development.
The company's co-founders also said in the prospectus that the company's goal is to help humanity safely navigate this period of technological transformation, open up new areas of scientific discovery and create unprecedented development opportunities.
As Anthropic prepares to officially list on Nasdaq, investors will closely watch its first-day performance. Whether the IPO receives an enthusiastic market reception will not only affect Anthropic's own valuation prospects but may also have a profound impact on the financing environment for the entire AI industry and future listing plans.
Related Articles

HK Stock Market Move | CATHAY PAC AIR (00293) rises over 3%; October passenger traffic up 4% year-on-year; JP Morgan bullish on its market share and yield advantages.

HK Stock Market Move | IMPACT THERAP-B (07630) rose over 15% against the market trend as Senaparib received EU approval for first-line maintenance treatment of ovarian cancer in the all-comer population.

UBS: Cuts CHINA RES MIXC (01209) target price to HK$52, maintains "Buy" rating.
HK Stock Market Move | CATHAY PAC AIR (00293) rises over 3%; October passenger traffic up 4% year-on-year; JP Morgan bullish on its market share and yield advantages.

HK Stock Market Move | IMPACT THERAP-B (07630) rose over 15% against the market trend as Senaparib received EU approval for first-line maintenance treatment of ovarian cancer in the all-comer population.

UBS: Cuts CHINA RES MIXC (01209) target price to HK$52, maintains "Buy" rating.






